{"source_content":"请务必阅读最后一页股票评级说明和免责声明1医药生物报告原因：定期报告2020H1血制品批签发数据跟踪维持评级上半年整体高速增长，各品种表现亮眼看好2020年8月11日行业研究/定期报告医药生物近一年市场表现半年度批签发数据跟踪➢2020H1国内累计批签发血制品4883.38万瓶，同比增长45.78%。各品种批签发数据跟踪➢人血白蛋白：累计批签发2957.28万瓶，同比增长43.72%，其中国产与进口各批签发1525.91万瓶、1431.37万瓶，分别占比51.60%、48.40%，进口白蛋白同比提升7.10个百分点；➢静注人免疫球蛋白（pH4）：累计批签发699.03万瓶，同比增长56.61%；➢人免疫球蛋白：；累计批签发88.67万瓶，同比增长792.87%；➢乙型肝炎人免疫球蛋白：累计批签发61.67万瓶，同比增长22.59%；➢破伤风人免疫球蛋白：累计批签发300.76万瓶，同比增长32.34%；➢狂犬病人免疫球蛋白：累计批签发534.42万瓶，同比增长28.02%；➢人凝血因子VIII：累计批签发97.74万瓶，同比增长60.15%；➢人凝血酶原复合物：累计批签发83.20万瓶，同比增长137.76%；➢人纤维蛋白原：累计批签发60.41万瓶，同比增长35.17%。上市公司批签发数据跟踪➢上海莱士：累计批签发血制品447.44万瓶，同比增长90.99%。分品种来看，白蛋白批签发188.07万瓶，同比增长54.05%；静丙批签发123.46万瓶，同比增长322.12%；破免批签发46.39万瓶，同比增长232.14%；八因子批签发32.96万瓶，同比增长424.11%；纤原批签发26.23万瓶，同比增长1065.65%；狂免批签发16.80万瓶，同比下降58.51%；肌丙批签发13.52万瓶，2019年无批签发。➢华兰生物：累计批签发血制品356.02万瓶，同比增长14.51%。分品种来看，白蛋白批签发123.42万瓶，同比增长2.77%；静丙批签发65.65万瓶，同比增长2.47%；破免批签发55.77万瓶，同比增长54.19%；PCC批签发33.74万瓶，同比增长157.23%；狂免批签发33.80万瓶，同比下降19.65%；八因子批签发29.58万瓶，同比增长22.49%；乙免批签发10.96万瓶，同比增长35.90%；肌丙批签发3.11万瓶，同比增分析师：刘建宏执业登记编码：S0760518030002电话：0351-8686724邮箱：liujianhong@sxzq.com太原市府西街69号国贸中心A座28层北京市西城区平安里西大街28号中海国际中心七层山西证券股份有限公司http://www.i618.com.cn证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明2长5.43%。➢天坛生物：累计批签发血制品477.81万瓶，同比增长23.50%。分品种来看，白蛋白批签发223.52万瓶，同比增长10.01%；静丙批签发152.75万瓶，同比增长35.17%；狂免批签发54.64万瓶，同比增长103.52%；破免批签发43.17万瓶，同比增长0.97%；肌丙批签发2.24万瓶，2019H1无批签发；乙免批签发1.12万瓶，同比增长1.85%；八因子批签发3673瓶，2019H1无批签发。➢卫光生物：累计批签发血制品167.50万瓶，同比增长35%。分品种来看，狂免批签发95.52万瓶，同比增长106.68%；白蛋白批签发36.96万瓶，同比下降6.81%；静丙批签发30万瓶，同比增长20.94%；破免批签发4.62万瓶，同比下降56.06%。➢博雅生物：累计批签发血制品182.22万瓶，同比增长76.26%。分品种来看，白蛋白批签发78.65万瓶，同比增长136.38%；静丙批签发41.41万瓶，同比增长64.83%；狂免批签发37.09万瓶，同比增长64.83%；肌丙批签发10.70万瓶，2019H1无批签发；纤原批签发10.68万瓶，同比下降45.55%；乙免批签发3.67万瓶，2019H1无批签发。➢双林生物：累计批签发血制品146.57万瓶，同比增长6.01%。分品种来看，狂免批签发46.99万瓶，同比下降31.59%；白蛋白批签发43.20万瓶，同比增长9.11%；静丙批签发31.10万瓶，同比增长171.94%；破免批签发25.29万瓶，同比增长36.33%。投资建议➢受疫情推动，2020H1血制品整体批签发量高速增长，各品种均实现较快增长。一季度静丙虽销售大幅增长，但其他血制品需求下降，行业市场整体有所下滑，但3月起国内疫情明显好转，医院就诊率逐步恢复，预计二季度起各类血制品销售已逐步恢复。另疫情导致上半年采浆减少，下半年上游原料血浆或将供给紧张，下游血制品存在涨价可能。行业景气度持续，我们维持看好观点，监管日益趋严，集中度有望继续提升，建议关注采浆能力强、生产规模大、产品丰富的优质血制品龙头企业华兰生物、天坛生物。风险提示：1）疫情变化风险；2）原料血浆供给不足风险；3）行业政策风险；4）产品安全风险；5）产品价格风险；6）研发与销售不达预期风险。证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明3目录1.半年度批签发数据跟踪...................................................................................................................................................71.1总批签发情况............................................................................................................................................................71.2各品种批签发情况....................................................................................................................................................72.各品种批签发数据跟踪.................................................................................................................................................82.1人血白蛋白................................................................................................................................................................82.2静注人免疫球蛋白（PH4）...................................................................................................................................102.3人免疫球蛋白..........................................................................................................................................................102.4乙型肝炎人免疫球蛋白...........................................................................................................................................112.5破伤风人免疫球蛋白..............................................................................................................................................122.6狂犬病人免疫球蛋白..............................................................................................................................................132.7人凝血因子VIII......................................................................................................................................................142.8人凝血酶原复合物..................................................................................................................................................152.9人纤维蛋白原..........................................................................................................................................................163.上市公司批签发数据跟踪.............................................................................................................................................173.1上海莱士..................................................................................................................................................................173.2华兰生物..................................................................................................................................................................193.3天坛生物..................................................................................................................................................................203.4卫光生物..................................................................................................................................................................213.5博雅生物..................................................................................................................................................................233.6双林生物..................................................................................................................................................................244.投资建议.........................................................................................................................................................................255.风险提示.........................................................................................................................................................................26证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明4图表目录图12011H1-2020H1血制品批签发量（万瓶）及同比....................................................................................................7图22019年-2020年血制品月度批签发量（万瓶）.......................................................................................................7图32016H1-2020H1血制品批签发量（万瓶）................................................................................................................7图42020H1各品种血制品批签发量（万瓶）................................................................................................................8图52020H1各品种血制品批签占比................................................................................................................................8图72019年-2020年白蛋白月度批签发量（万瓶）......................................................................................................9图82016H1-2020H1白蛋白批签发量（万瓶）................................................................................................................9图92019H1与2020H1国产、进口白蛋白批签发占比..........................................................................................................9图102020H1国产各生产企业白蛋白批签发占比...................................................................................................................9图112019年-2020年静丙月度批签发量（万瓶）................................................................................................................10图122011H1-2020H1静丙批签发量（万瓶）及同比..................................................................................................10图132016H1-2020H1静丙批签发量（万瓶）..............................................................................................................10图142020H1各企业静丙批签发占比............................................................................................................................10图152019年-2020年肌丙月度批签发量（万瓶）...............................................................................................................11图162011H1-2020H1肌丙批签发量（万瓶）及同比...........................................................................................................11图172016H1-2020H1肌丙批签发量（万瓶）..............................................................................................................11图182020H1各企业肌丙批签发占比............................................................................................................................11图192019年-2020年乙免月度批签发量（万瓶）...............................................................................................................12图202011H1-2020H1乙免批签发量（万瓶）及同比...........................................................................................................12图212016H1-2020H1乙免批签发量（万瓶）..............................................................................................................12图222020H1各企业乙免批签发占比............................................................................................................................12图232019年-2020年破免月度批签发量（万瓶）...............................................................................................................13图242011H1-2020H1破免批签发量（万瓶）及同比...........................................................................................................13图252016H1-2020H1破免批签发量（万瓶）....................................................................................................................13图262020H1各企业破免批签发占比............................................................................................................................13图272019年-2020年狂免月度批签发量（万瓶）...............................................................................................................14图282011H1-2020H1狂免批签发量（万瓶）及同比..........................................................................................................14图2920161H1-2020H1狂免批签发量（万瓶）..................................................................................................................14证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明5图302020H1各企业狂免批签发占比............................................................................................................................14图312019年-2020年八因子月度批签发量（万瓶）............................................................................................................15图322011H1-2020H1八因子批签发量（万瓶）及同比........................................................................................................15图332016H1-2020H1八因子批签发量（万瓶）.................................................................................................................15图342020H1各企业八因子批签发占比........................................................................................................................15图352019年-2020年PCC月度批签发量（万瓶）..............................................................................................................16图362011H1-2020H1PCC批签发量（万瓶）及同比...........................................................................................................16图372016H1-2020H1PCC批签发量（万瓶）....................................................................................................................16图382020H1各企业PCC批签发占比..........................................................................................................................16图392019年-2020年纤原月度批签发量（万瓶）...............................................................................................................17图402011H1-2020H1纤原批签发量（万瓶）及同比...........................................................................................................17图412016H1-2020H1纤原批签发量（万瓶）....................................................................................................................17图422020H1各企业纤原批签发占比............................................................................................................................17图442019年-2020年上海莱士血制品月度批签发量（万瓶）..............................................................................................18图452016H1-2020H1上海莱士血制品批签发量（万瓶）....................................................................................................18图462020H1上海莱士各品种血制品批签发量（万瓶）........................................................................................................18图472020H1上海莱士各品种血制品批签发占比..................................................................................................................18图492019年-2020年华兰生物血制品月度批签发量（万瓶）..............................................................................................19图502016H1-2020H1华兰生物血制品批签发量（万瓶）....................................................................................................19图512020H1华兰生物各品种血制品批签发量（万瓶）........................................................................................................20图522020H1华兰生物各品种血制品批签发占比..................................................................................................................20图542019年-2020年天坛生物血制品月度批签发量（万瓶）..............................................................................................21图552016H1-2020H1天坛生物血制品批签发量（万瓶）....................................................................................................21图562020H1天坛生物各品种血制品批签发量（万瓶）........................................................................................................21图572020H1天坛生物各品种血制品批签发占比..................................................................................................................21图592019年-2020年卫光生物血制品月度批签发量（万瓶）..............................................................................................22图602016H1-2020H1卫光生物血制品批签发量（万瓶）....................................................................................................22图612020H1卫光生物各品种血制品批签发量（万瓶）........................................................................................................22图622020H1卫光生物各品种血制品批签发占比..................................................................................................................22证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明6图642019年-2020年博雅生物血制品月度批签发量（万瓶）..............................................................................................23图652016H1-2020H1博雅生物血制品批签发量（万瓶）....................................................................................................23图662020H1博雅生物各品种血制品批签发量（万瓶）........................................................................................................24图672020H1博雅生物各品种血制品批签发占比..................................................................................................................24图692019年-2020年双林生物血制品月度批签发量（万瓶）..............................................................................................25图702016H1-2020H1双林生物血制品批签发量（万瓶）....................................................................................................25图712020H1双林生物各品种血制品批签发量（万瓶）........................................................................................................25图722020H1双林生物各品种血制品批签发占比..................................................................................................................25证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明71.半年度批签发数据跟踪1.1总批签发情况2020H1国内累计批签发血制品4883.38万瓶，同比增长45.78%。图12011H1-2020H1血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图22019年-2020年血制品月度批签发量（万瓶）图32016H1-2020H1血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。1.2各品种批签发情况从各品种血制品批签发情况来看，作为血制品主要品种，白蛋白2020H1批签发2957.28万瓶，占比-10.00%0.00%10.00%20.00%30.00%40.00%50.00%0.001000.002000.003000.004000.005000.006000.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H10.00200.00400.00600.00800.001000.001200.001400.000.001000.002000.003000.004000.005000.006000.002016H12016H22017H12017H22018H12018H22019H12019H22020H1证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明860.56%。图42020H1各品种血制品批签发量（万瓶）图52020H1各品种血制品批签占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：➢人血白蛋白：简称白蛋白，统一折算为标准规格10g/瓶；➢静注人免疫球蛋白（pH4）：简称静丙，统一折算为标准规格2.5g/瓶；➢人免疫球蛋白：简称肌丙，统一折算为标准规格300mg/瓶；➢乙型肝炎人免疫球蛋白：简称乙免，统一折算为标准规格200IU/瓶；➢破伤风人免疫球蛋白：简称破免，统一折算为标准规格250IU/瓶；➢狂犬病人免疫球蛋白：简称狂免，统一折算为标准规格200IU/瓶；➢人凝血因子VIII：简称八因子，统一折算为标准规格200IU/瓶；➢人凝血酶原复合物：简称PCC，统一折算为标准规格200IU/瓶；➢人纤维蛋白原：简称纤原，统一折算为标准规格0.5g/瓶。2.各品种批签发数据跟踪2.1人血白蛋白2020H1白蛋白累计批签发2957.28万瓶，同比增长43.72%，其中国产与进口各批签发1525.91万瓶、1431.37万瓶，分别占比51.60%、48.40%，进口白蛋白同比提升7.10个百分点。从国产各生产企业批签发情况来看，天坛生物批签发223.52万瓶，占比（国产白蛋白）21.64%，位居首位；其次为上海莱士，批签发188.07万瓶，占比（国产白蛋白）18.20%；泰邦生物、华兰生物各批签发164.78万瓶、123.42万瓶，分别占比（国产白蛋白）15.95%、11.95%。2957.28699.03534.42300.7697.9488.6783.2061.6760.410.00500.001000.001500.002000.002500.003000.003500.00白蛋白静丙狂免破免八因子肌丙PCC乙免纤原60.56%14.31%10.94%6.16%2.01%1.82%1.70%1.26%1.24%白蛋白静丙狂免破免八因子肌丙PCC乙免纤原证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明9图62011H1-2020H1白蛋白批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图72019年-2020年白蛋白月度批签发量（万瓶）图82016H1-2020H1白蛋白批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图92019H1与2020H1国产、进口白蛋白批签发占比图102020H1国产各生产企业白蛋白批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究注：人血白蛋白简称白蛋白，统一折算为标准规格10g/瓶。圆环图内圈为2019年，外圈为2020年。-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%50.00%0.00500.001000.001500.002000.002500.003000.003500.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H10.00100.00200.00300.00400.00500.00600.00700.00800.000.00500.001000.001500.002000.002500.003000.003500.002016H12016H22017H12017H22018H12018H22019H12019H22020H158.70%41.30%51.60%48.40%国产进口21.64%18.20%15.95%11.95%32.27%天坛生物上海莱士泰邦生物华兰生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明102.2静注人免疫球蛋白（pH4）2020H1静丙累计批签发699.03万瓶，同比增长56.61%，其中天坛生物批签发152.75万瓶，占比21.85%，位居首位；其次为上海莱士，批签发123.46万瓶，占比17.66%；泰邦生物批签发109.19万瓶，占比15.62%。图112019年-2020年静丙月度批签发量（万瓶）图122011H1-2020H1静丙批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图132016H1-2020H1静丙批签发量（万瓶）图142020H1各企业静丙批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：静注人免疫球蛋白（pH4）简称静丙，统一折算为标准规格2.5g/瓶。2.3人免疫球蛋白2020H1肌丙累计批签发88.67万瓶，同比增长792.87%，其中博晖创新、德源生物各批签发29.86万瓶、18.24万瓶，分别占比33.68%、20.57%。0.0050.00100.00150.00200.00250.00-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%0.00100.00200.00300.00400.00500.00600.00700.00800.000.00100.00200.00300.00400.00500.00600.00700.00800.002016H12016H22017H12017H22018H12018H22019H12019H22020H121.85%17.66%15.62%9.39%35.47%天坛生物上海莱士泰邦生物华兰生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明11图152019年-2020年肌丙月度批签发量（万瓶）图162011H1-2020H1肌丙批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图172016H1-2020H1肌丙批签发量（万瓶）图182020H1各企业肌丙批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人免疫球蛋白简称肌丙，统一折算为标准规格300mg/瓶。2.4乙型肝炎人免疫球蛋白2020H1乙免累计批签发61.67万瓶，同比增长22.59%，其中远大蜀阳累计批签发41.67万瓶，占比67.57%，华兰生物批签发10.96万瓶，占比17.77%。0.005.0010.0015.0020.0025.0030.0035.0040.0045.0050.00-200.00%-100.00%0.00%100.00%200.00%300.00%400.00%500.00%600.00%700.00%800.00%900.00%0.0010.0020.0030.0040.0050.0060.0070.0080.0090.00100.000.0020.0040.0060.0080.00100.00120.002016H12016H22017H12017H22018H12018H22019H12019H22020H133.68%20.57%15.25%12.39%12.07%3.51%2.53%博晖创新德源生物上海莱士派斯菲科博雅生物华兰生物天坛生物证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明12图192019年-2020年乙免月度批签发量（万瓶）图202011H1-2020H1乙免批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图212016H1-2020H1乙免批签发量（万瓶）图222020H1各企业乙免批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：乙型肝炎人免疫球蛋白简称乙免，统一折算为标准规格200IU/瓶。2.5破伤风人免疫球蛋白2020H1破免累计批签发300.76万瓶，同比增长32.34%，其中泰邦生物批签发82.37万瓶，占比27.39%，位居首位，华兰生物批签发55.77万瓶，占比18.54%。0.005.0010.0015.0020.0025.0030.00-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%0.0020.0040.0060.0080.00100.00120.00140.00160.000.0020.0040.0060.0080.00100.00120.002016H12016H22017H12017H22018H12018H22019H12019H22020H167.57%17.77%6.89%5.96%1.82%远大蜀阳华兰生物泰邦生物博雅生物天坛生物证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明13图232019年-2020年破免月度批签发量（万瓶）图242011H1-2020H1破免批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图252016H1-2020H1破免批签发量（万瓶）图262020H1各企业破免批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：破伤风人免疫球蛋白简称破免，统一折算为标准规格250IU/瓶。2.6狂犬病人免疫球蛋白2020H1狂免累计批签发534.42万瓶，同比增长28.02%，其中泰邦生物批签发103.27万瓶，占比19.32%，位居首位；卫光生物、远大蜀阳各批签发95.92万瓶、94.84万瓶，分别占比17.95%、17.75%。0.0010.0020.0030.0040.0050.0060.0070.0080.0090.00-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%0.0050.00100.00150.00200.00250.00300.00350.000.0050.00100.00150.00200.00250.00300.00350.002016H12016H22017H12017H22018H12018H22019H12019H22020H127.39%18.54%15.42%14.35%13.03%8.41%1.54%1.31%泰邦生物华兰生物上海莱士天坛生物远大蜀阳双林生物卫光生物博晖创新证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明14图272019年-2020年狂免月度批签发量（万瓶）图282011H1-2020H1狂免批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图2920161H1-2020H1狂免批签发量（万瓶）图302020H1各企业狂免批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：狂犬病人免疫球蛋白简称狂免，统一折算为标准规格200IU/瓶。2.7人凝血因子VIII2020H1八因子累计批签发97.74万瓶，同比增长60.15%，其中上海莱士批签发32.96万瓶，占比33.66%，位居首位，华兰生物、泰邦生物各批签发29.58万瓶、21.66万瓶，分别占比30.21%、22.12%。0.0020.0040.0060.0080.00100.00120.00140.00160.00180.00-50.00%0.00%50.00%100.00%150.00%200.00%0.00100.00200.00300.00400.00500.00600.000.00100.00200.00300.00400.00500.00600.00700.00800.002016H12016H22017H12017H22018H12018H22019H12019H22020H119.32%17.95%17.75%10.22%8.79%6.94%6.61%6.32%3.14%2.95%泰邦生物卫光生物远大蜀阳天坛生物双林生物博雅生物南岳生物华兰生物上海莱士博晖创新证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明15图312019年-2020年八因子月度批签发量（万瓶）图322011H1-2020H1八因子批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图332016H1-2020H1八因子批签发量（万瓶）图342020H1各企业八因子批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人凝血因子VIII简称八因子，统一折算为标准规格200IU/瓶。2.8人凝血酶原复合物2020H1PCC累计批签发83.20万瓶，同比增长137.76%，其中泰邦生物、华兰生物各批签发49.46万瓶、33.74万瓶，分别占比59.45%、40.55%。0.005.0010.0015.0020.0025.0030.0035.00-50.00%0.00%50.00%100.00%150.00%200.00%250.00%300.00%0.0020.0040.0060.0080.00100.00120.000.0020.0040.0060.0080.00100.00120.002016H12016H22017H12017H22018H12018H22019H12019H22020H133.66%30.21%22.12%13.64%0.38%上海莱士华兰生物泰邦生物绿十字天坛生物证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明16图352019年-2020年PCC月度批签发量（万瓶）图362011H1-2020H1PCC批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图372016H1-2020H1PCC批签发量（万瓶）图382020H1各企业PCC批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人凝血酶原复合物简称PCC，统一折算为标准规格200IU/瓶。2.9人纤维蛋白原2020H1纤维蛋白原累计批签发60.41万瓶，同比增长35.17%，其中上海莱士批签发26.23万瓶，占比43.42%，位居首位，泰邦生物、博雅生物各批签发15.91万瓶、10.68万瓶，分别占比26.34%、17.69%。0.005.0010.0015.0020.0025.00-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%120.00%140.00%160.00%0.0010.0020.0030.0040.0050.0060.0070.0080.0090.000.0010.0020.0030.0040.0050.0060.0070.0080.0090.002016H12016H22017H12017H22018H12018H22019H12019H22020H159.45%40.55%泰邦生物华兰生物证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明17图392019年-2020年纤原月度批签发量（万瓶）图402011H1-2020H1纤原批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图412016H1-2020H1纤原批签发量（万瓶）图422020H1各企业纤原批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人纤维蛋白原简称纤原，统一折算为标准规格0.5g/瓶。3.上市公司批签发数据跟踪3.1上海莱士2020H1上海莱士累计批签发血制品447.44万瓶，同比增长90.99%。分品种来看，白蛋白批签发188.07万瓶，同比增长54.05%；静丙批签发123.46万瓶，同比增长322.12%；破免批签发46.39万瓶，同比增长232.14%；八因子批签发32.96万瓶，同比增长424.11%；纤原批签发26.23万瓶，同比增长1065.65%；狂免批签发16.80万瓶，同比下降58.51%；肌丙批签发13.52万瓶，2019年无批签发。0.002.004.006.008.0010.0012.0014.0016.0018.00-100.00%0.00%100.00%200.00%300.00%400.00%500.00%600.00%0.0010.0020.0030.0040.0050.0060.0070.000.0010.0020.0030.0040.0050.0060.0070.002016H12016H22017H12017H22018H12018H22019H12019H22020H143.42%26.34%17.69%6.98%5.57%上海莱士泰邦生物博雅生物派斯菲科绿十字证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明18图432011H1-2020H1上海莱士血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图442019年-2020年上海莱士血制品月度批签发量（万瓶）图452016H1-2020H1上海莱士血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图462020H1上海莱士各品种血制品批签发量（万瓶）图472020H1上海莱士各品种血制品批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%0.0050.00100.00150.00200.00250.00300.00350.00400.00450.00500.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H10.0020.0040.0060.0080.00100.00120.00140.000.00100.00200.00300.00400.00500.00600.002016H12016H22017H12017H22018H12018H22019H12019H22020H1188.07123.4646.3932.9626.2316.8013.520.0020.0040.0060.0080.00100.00120.00140.00160.00180.00200.00白蛋白静丙破免八因子纤原狂免肌丙42.03%27.59%10.37%7.37%5.86%3.76%3.02%白蛋白静丙破免八因子纤原狂免肌丙证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明193.2华兰生物2020H1华兰生物累计批签发血制品356.02万瓶，同比增长14.51%。分品种来看，白蛋白批签发123.42万瓶，同比增长2.77%；静丙批签发65.65万瓶，同比增长2.47%；破免批签发55.77万瓶，同比增长54.19%；PCC批签发33.74万瓶，同比增长157.23%；狂免批签发33.80万瓶，同比下降19.65%；八因子批签发29.58万瓶，同比增长22.49%；乙免批签发10.96万瓶，同比增长35.90%；肌丙批签发3.11万瓶，同比增长5.43%。图482011H1-2020H1华兰生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图492019年-2020年华兰生物血制品月度批签发量（万瓶）图502016H1-2020H1华兰生物血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%50.00%0.0050.00100.00150.00200.00250.00300.00350.00400.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H10.0020.0040.0060.0080.00100.00120.000.0050.00100.00150.00200.00250.00300.00350.00400.00450.00500.002016H12016H22017H12017H22018H12018H22019H12019H22020H1证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明20图512020H1华兰生物各品种血制品批签发量（万瓶）图522020H1华兰生物各品种血制品批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.3天坛生物2020H1天坛生物累计批签发血制品477.81万瓶，同比增长23.50%。分品种来看，白蛋白批签发223.52万瓶，同比增长10.01%；静丙批签发152.75万瓶，同比增长35.17%；狂免批签发54.64万瓶，同比增长103.52%；破免批签发43.17万瓶，同比增长0.97%；肌丙批签发2.24万瓶，2019H1无批签发；乙免批签发1.12万瓶，同比增长1.85%；八因子批签发3673瓶，2019H1无批签发。图532011H1-2020H1天坛生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所123.4265.6555.7733.7433.8029.5810.963.110.0020.0040.0060.0080.00100.00120.00140.00白蛋白静丙破免PCC狂免八因子乙免肌丙34.67%18.44%15.66%9.48%9.49%8.31%3.08%0.87%白蛋白静丙破免PCC狂免八因子乙免肌丙-100.00%0.00%100.00%200.00%300.00%400.00%500.00%0.00100.00200.00300.00400.00500.00600.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H1证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明21图542019年-2020年天坛生物血制品月度批签发量（万瓶）图552016H1-2020H1天坛生物血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图562020H1天坛生物各品种血制品批签发量（万瓶）图572020H1天坛生物各品种血制品批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.4卫光生物2020H1卫光生物累计批签发血制品167.50万瓶，同比增长35%。分品种来看，狂免批签发95.52万瓶，同比增长106.68%；白蛋白批签发36.96万瓶，同比下降6.81%；静丙批签发30万瓶，同比增长20.94%；破免批签发4.62万瓶，同比下降56.06%。0.0020.0040.0060.0080.00100.00120.00140.000.00100.00200.00300.00400.00500.00600.002016H12016H22017H12017H22018H12018H22019H12019H22020H1223.52152.7554.6443.172.241.120.370.0050.00100.00150.00200.00250.00白蛋白静丙狂免破免肌丙乙免八因子46.78%31.97%11.44%9.03%0.47%0.24%0.08%白蛋白静丙狂免破免肌丙乙免八因子证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明22图582011H1-2020H1卫光生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图592019年-2020年卫光生物血制品月度批签发量（万瓶）图602016H1-2020H1卫光生物血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图612020H1卫光生物各品种血制品批签发量（万瓶）图622020H1卫光生物各品种血制品批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%120.00%140.00%160.00%0.0020.0040.0060.0080.00100.00120.00140.00160.00180.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H10.005.0010.0015.0020.0025.0030.0035.0040.0045.0050.000.0020.0040.0060.0080.00100.00120.00140.00160.00180.002016H12016H22017H12017H22018H12018H22019H12019H22020H195.9236.9630.004.620.0020.0040.0060.0080.00100.00120.00狂免白蛋白静丙破免57.26%22.06%17.91%2.76%狂免白蛋白静丙破免证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明233.5博雅生物2020H1博雅生物累计批签发血制品182.22万瓶，同比增长76.26%。分品种来看，白蛋白批签发78.65万瓶，同比增长136.38%；静丙批签发41.41万瓶，同比增长64.83%；狂免批签发37.09万瓶，同比增长64.83%；肌丙批签发10.70万瓶，2019H1无批签发；纤原批签发10.68万瓶，同比下降45.55%；乙免批签发3.67万瓶，2019H1无批签发。图632011H1-2020H1博雅生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图642019年-2020年博雅生物血制品月度批签发量（万瓶）图652016H1-2020H1博雅生物血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所-500.00%0.00%500.00%1000.00%1500.00%2000.00%2500.00%0.0020.0040.0060.0080.00100.00120.00140.00160.00180.00200.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H10.0010.0020.0030.0040.0050.0060.000.0020.0040.0060.0080.00100.00120.00140.00160.00180.00200.002016H12016H22017H12017H22018H12018H22019H12019H22020H1证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明24图662020H1博雅生物各品种血制品批签发量（万瓶）图672020H1博雅生物各品种血制品批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.6双林生物2020H1双林生物累计批签发血制品146.57万瓶，同比增长6.01%。分品种来看，狂免批签发46.99万瓶，同比下降31.59%；白蛋白批签发43.20万瓶，同比增长9.11%；静丙批签发31.10万瓶，同比增长171.94%；破免批签发25.29万瓶，同比增长36.33%。图682011H1-2020H1双林生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所78.6541.4137.0910.7010.683.670.0010.0020.0030.0040.0050.0060.0070.0080.0090.00白蛋白静丙狂免肌丙纤原乙免43.16%22.73%20.36%5.87%5.86%2.02%白蛋白静丙狂免肌丙纤原乙免-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%0.0020.0040.0060.0080.00100.00120.00140.00160.002011H12012H12013H12014H12015H12016H12017H12018H12019H12020H1证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明25图692019年-2020年双林生物血制品月度批签发量（万瓶）图702016H1-2020H1双林生物血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图712020H1双林生物各品种血制品批签发量（万瓶）图722020H1双林生物各品种血制品批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。4.投资建议受疫情推动，2020H1血制品整体批签发量高速增长，各品种均实现较快增长。一季度静丙虽销售大幅增长，但其他血制品需求下降，行业市场整体有所下滑，但3月起国内疫情明显好转，医院就诊率逐步恢复，预计二季度起各类血制品销售已逐步恢复。另疫情导致上半年采浆减少，下半年上游原料血浆或将供给紧张，下游血制品存在涨价可能。行业景气度持续，我们维持看好观点，监管日益趋严，集中度有望继续提升，建议关注采浆能力强、生产规模大、产品丰富的优质血制品龙头企业华兰生物、天坛生物。0.0010.0020.0030.0040.0050.0060.000.0020.0040.0060.0080.00100.00120.00140.00160.00180.002016H12016H22017H12017H22018H12018H22019H12019H22020H146.9943.2031.1025.290.005.0010.0015.0020.0025.0030.0035.0040.0045.0050.00狂免白蛋白静丙破免32.06%29.47%21.22%17.25%狂免白蛋白静丙破免证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明265.风险提示1）疫情变化风险；2）原料血浆供给不足风险；3）行业政策风险；4）产品安全风险；5）产品价格风险；6）研发与销售不达预期风险。证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明27分析师承诺：本人具有中国证券业协会授予的证券投资咨询执业资格并注册为证券分析师，本人承诺，以勤勉的职业态度，独立、客观地出具本报告。本报告清晰准确地反映本人的研究观点。本人不曾因，不因，也将不会因本报告中的具体推荐意见或观点而直接或间接受到任何形式的补偿。本人承诺不利用自己的身份、地位和执业过程中所掌握的信息为自己或他人谋取私利。投资评级的说明：——报告发布后的6个月内上市公司股票涨跌幅相对同期上证指数/深证成指的涨跌幅为基准——股票投资评级标准：买入：相对强于市场表现20%以上增持：相对强于市场表现5～20%中性：相对市场表现在-5%～+5%之间波动减持：相对弱于市场表现5%以下——行业投资评级标准：看好：行业超越市场整体表现中性：行业与整体市场表现基本持平看淡：行业弱于整体市场表现免责声明：山西证券股份有限公司(以下简称“本公司”)具备证券投资咨询业务资格。本报告是基于本公司认为可靠的已公开信息，但本公司不保证该等信息的准确性或完整性。入市有风险，投资需谨慎。在任何情况下，本报告中的信息或所表述的意见并不构成对任何人的投资建议。在任何情况下，本公司不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。本报告所载的资料、意见及推测仅反映本所于发布本报告当日的判断。在不同时期，本所可发出与本报告所载资料、意见及推测不一致的报告。本公司或其关联机构在法律许可的情况下可能持有或交易本报告中提到的上市公司所发行的证券或投资标的，还可能为或争取为这些公司提供投资银行或财务顾问服务。客户应当考虑到本公司可能存在可能影响本报告客观性的利益冲突。本公司在知晓范围内履行披露义务。本报告的版权归本公司所有。本公司对本报告保留一切权利。未经本公司事先书面授权，本报告的任何部分均不得以任何方式制作任何形式的拷贝、复印件或复制品，或再次分发给任何其他人，或以任何侵犯本公司版权的其他方式使用。否则，本公司将保留随时追究其法律责任的权利。依据《发布证券研究报告执业规范》规定特此声明，禁止我司员工将我司证券研究报告私自提供给未经我司授权的任何公众媒体或者其他机构；禁止任何公众媒体或者其他机构未经授权私自刊载或者转发我司的证券研究报告。刊载或者转发我司证券研究报告的授权必须通过签署协议约定，且明确由被授权机构承担相关刊载或者转发责任。依据《发布证券研究报告执业规范》规定特此提示我司证券研究业务客户不要将我司证券研究报告转发给他人，提示我司证券研究业务客户及公众投资者慎重使用公众媒体刊载的证券研究报告。依据《证券期货经营机构及其工作人员廉洁从业规定》和《证券经营机构及其工作人员廉洁从业实施细则》规定特此告知我司证券研究业务客户遵守廉洁从业规定。山西证券研究所：太原北京太原市府西街69号国贸中心A座28层电话：0351-8686981http://www.i618.com.cn北京市西城区平安里西大街28号中海国际中心七层电话：010-83496336","data":[{"id":"1","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1国内累计批签发血制品4883.38万瓶","content_offset":["114","139"],"indicators":[{"indicator_name":"批签发量","indicator_value":["4883.38万瓶","130","139"],"indicator_element":{"时间":["2020H1","114","120"],"区域":["国内","120","122"],"行业":["血制品","127","130"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长45.78%","content_offset":["140","150"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["45.78%","144","150"],"indicator_element":{"时间":["2020H1","114","120"],"区域":["国内","120","122"],"行业":["血制品","40","43"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发2957.28万瓶","content_offset":["168","182"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2957.28万瓶","173","182"],"indicator_element":{"行业":["血制品","127","130"],"产品":["人血白蛋白","162","167"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长43.72%","content_offset":["183","193"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["43.72%","187","193"],"indicator_element":{"行业":["血制品","127","130"],"产品":["人血白蛋白","162","167"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"其中国产与进口各批签发1525.91万瓶、1431.37万瓶","content_offset":["194","224"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1525.91万瓶","205","214"],"indicator_element":{"渠道":["国产","196","198"],"行业":["血制品","127","130"],"产品":["人血白蛋白","162","167"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["1431.37万瓶","215","224"],"indicator_element":{"渠道":["进口","199","201"],"行业":["血制品","127","130"],"产品":["人血白蛋白","162","167"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"分别占比51.60%、48.40%","content_offset":["225","242"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["51.60%","229","235"],"indicator_element":{"渠道":["国产","196","198"],"行业":["血制品","127","130"],"产品":["人血白蛋白","162","167"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量占比","indicator_value":["48.40%","236","242"],"indicator_element":{"渠道":["进口","199","201"],"行业":["血制品","127","130"],"产品":["人血白蛋白","162","167"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发699.03万瓶","content_offset":["276","289"],"indicators":[{"indicator_name":"批签发量","indicator_value":["699.03万瓶","281","289"],"indicator_element":{"产品":["静注人免疫球蛋白","262","270"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长56.61%","content_offset":["290","300"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["56.61%","294","300"],"indicator_element":{"产品":["静注人免疫球蛋白","262","270"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发88.67万瓶","content_offset":["310","322"],"indicators":[{"indicator_name":"批签发量","indicator_value":["88.67万瓶","315","322"],"indicator_element":{"产品":["人免疫球蛋白","264","270"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长792.87%","content_offset":["323","334"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["792.87%","327","334"],"indicator_element":{"产品":["人免疫球蛋白","264","270"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发61.67万瓶","content_offset":["347","359"],"indicators":[{"indicator_name":"批签发量","indicator_value":["61.67万瓶","352","359"],"indicator_element":{"产品":["乙型肝炎人免疫球蛋白","336","346"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长22.59%","content_offset":["360","370"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["22.59%","364","370"],"indicator_element":{"产品":["乙型肝炎人免疫球蛋白","336","346"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发300.76万瓶","content_offset":["382","395"],"indicators":[{"indicator_name":"批签发量","indicator_value":["300.76万瓶","387","395"],"indicator_element":{"产品":["破伤风人免疫球蛋白","372","381"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长32.34%","content_offset":["396","406"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["32.34%","400","406"],"indicator_element":{"产品":["破伤风人免疫球蛋白","372","381"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发534.42万瓶","content_offset":["418","431"],"indicators":[{"indicator_name":"批签发量","indicator_value":["534.42万瓶","423","431"],"indicator_element":{"产品":["狂犬病人免疫球蛋白","408","417"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长28.02%","content_offset":["432","442"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["28.02%","436","442"],"indicator_element":{"产品":["狂犬病人免疫球蛋白","408","417"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发97.74万瓶","content_offset":["454","466"],"indicators":[{"indicator_name":"批签发量","indicator_value":["97.74万瓶","459","466"],"indicator_element":{"产品":["人凝血因子VIII","444","453"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长60.15%","content_offset":["467","477"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["60.15%","471","477"],"indicator_element":{"产品":["人凝血因子VIII","444","453"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发83.20万瓶","content_offset":["488","500"],"indicators":[{"indicator_name":"批签发量","indicator_value":["83.20万瓶","493","500"],"indicator_element":{"产品":["人凝血酶原复合物","479","487"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长137.76%","content_offset":["501","512"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["137.76%","505","512"],"indicator_element":{"产品":["人凝血酶原复合物","479","487"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"累计批签发60.41万瓶","content_offset":["521","533"],"indicators":[{"indicator_name":"批签发量","indicator_value":["60.41万瓶","526","533"],"indicator_element":{"产品":["人纤维蛋白原","514","520"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长35.17%","content_offset":["534","544"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["35.17%","538","544"],"indicator_element":{"产品":["人纤维蛋白原","514","520"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1白蛋白累计批签发2957.28万瓶","content_offset":["15870","15893"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2957.28万瓶","15884","15893"],"indicator_element":{"时间":["2020H1","15870","15876"],"产品":["白蛋白","15876","15879"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1静丙累计批签发699.03万瓶","content_offset":["17076","17097"],"indicators":[{"indicator_name":"批签发量","indicator_value":["699.03万瓶","17089","17097"],"indicator_element":{"时间":["2020H1","17076","17082"],"产品":["静丙","17082","17084"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1肌丙累计批签发88.67万瓶","content_offset":["17420","17440"],"indicators":[{"indicator_name":"批签发量","indicator_value":["88.67万瓶","17433","17440"],"indicator_element":{"时间":["2020H1","17420","17426"],"产品":["肌丙","17426","17428"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长792.87%","content_offset":["323","334"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["792.87%","327","334"],"indicator_element":{"时间":["2020H1","1850","1856"],"产品":["肌丙","749","751"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1乙免累计批签发61.67万瓶","content_offset":["18069","18089"],"indicators":[{"indicator_name":"批签发量","indicator_value":["61.67万瓶","18082","18089"],"indicator_element":{"时间":["2020H1","18069","18075"],"产品":["乙免","18075","18077"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长22.59%","content_offset":["360","370"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["22.59%","364","370"],"indicator_element":{"时间":["2020H1","1850","1856"],"产品":["乙免","959","961"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1破免累计批签发300.76万瓶","content_offset":["18767","18788"],"indicators":[{"indicator_name":"批签发量","indicator_value":["300.76万瓶","18780","18788"],"indicator_element":{"时间":["2020H1","18767","18773"],"产品":["破免","18773","18775"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长32.34%","content_offset":["396","406"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["32.34%","400","406"],"indicator_element":{"时间":["2020H1","1850","1856"],"产品":["破免","648","650"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1狂免累计批签发534.42万瓶","content_offset":["19393","19414"],"indicators":[{"indicator_name":"批签发量","indicator_value":["534.42万瓶","19406","19414"],"indicator_element":{"时间":["2020H1","19393","19399"],"产品":["狂免","19399","19401"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长28.02%","content_offset":["432","442"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["28.02%","436","442"],"indicator_element":{"时间":["2020H1","1850","1856"],"产品":["狂免","725","727"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1八因子累计批签发97.74万瓶","content_offset":["20093","20114"],"indicators":[{"indicator_name":"批签发量","indicator_value":["97.74万瓶","20107","20114"],"indicator_element":{"时间":["2020H1","20093","20099"],"产品":["八因子","20099","20102"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长60.15%","content_offset":["467","477"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["60.15%","471","477"],"indicator_element":{"时间":["2020H1","1850","1856"],"产品":["八因子","673","676"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1PCC累计批签发83.20万瓶","content_offset":["20804","20825"],"indicators":[{"indicator_name":"批签发量","indicator_value":["83.20万瓶","20818","20825"],"indicator_element":{"时间":["2020H1","20804","20810"],"产品":["PCC","20810","20813"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长137.76%","content_offset":["501","512"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["137.76%","505","512"],"indicator_element":{"时间":["2020H1","1850","1856"],"产品":["PCC","884","887"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"2020H1纤维蛋白原累计批签发60.41万瓶","content_offset":["21416","21439"],"indicators":[{"indicator_name":"批签发量","indicator_value":["60.41万瓶","21432","21439"],"indicator_element":{"时间":["2020H1","21416","21422"],"产品":["纤维蛋白原","21422","21427"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020H1血制品批签发数据跟踪：上半年整体高速增长，各品种表现亮眼.pdf","content":"同比增长35.17%","content_offset":["534","544"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["35.17%","538","544"],"indicator_element":{"时间":["2020H1","1850","1856"],"产品":["纤维蛋白原","515","520"]},"indicator_supplement":{"属性":""}}]}]}